Efficacy and Safety of DLBS3233 in Subjects With Polycystic Ovary Syndrome (PCOS)

Dexa Medica Group124 enrolled

Overview

This is a 2-arm, randomized, double-blind, double-dummy, and controlled clinical study, with 6 months of treatment to evaluate the clinical and metabolic efficacy of DLBS3233 in improving reproductive parameters and to evaluate the safety of DLBS3233 in women with polycystic ovary syndrome compared with metformin, as an active control.

There will be 2 groups of treatment; each group will consist of 62 subjects with the treatment regimens : * Treatment I : 1 capsule of DLBS3233 100 mg (once daily) and 1 placebo caplet of Metformin XR (twice daily) * Treatment II : 1 caplet of Metformin XR 750 mg (twice daily) and 1 placebo capsule of DLBS3233 (once daily) for 6 months of treatment. Clinical examination to evaluate the efficacy of the investigational drug will be performed at baseline and every interval of 1 month. Laboratory examinations to evaluate the metabolic efficacy parameters and ultrasonography (USG) examination will be performed at baseline, Month 3rd, and end of study (Month 6th). In addition to that, USG will also be performed about 2 weeks after Month 3rd (Month 3.5th) and after Month 5th (Month 5.5th). Laboratory examinations to evaluate the reproductive efficacy parameters (reproductive hormone levels) and safety, at baseline and Month 6th (end of study). General counseling on lifestyle modification will be provided to the subjects by the assigned Nutritionist. All study subjects should follow a lifestyle modification. Evaluation on subjects' performance on lifestyle modification will be conducted every follow-up visit by Investigator, but particularly at baseline, Month 3rd, and end of study (Month 6th) by the Nutritionist.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

124

Conditions

Polycystic Ovary Syndrome (PCOS)

Interventions

DLBS3233DRUG

1 DLBS3233 capsule 100 mg once daily for 6 months

Metformin XRDRUG

1 Metformin XR caplet 750 mg twice daily for 6 months

Placebo caplet of Metformin XRDRUG

1 placebo caplet of Metformin XR twice daily for 6 months

Eligibility

Sex: FEMALEMin age: 18 YearsMax age: 40 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Female subjects in reproductive age (i.e. 18-40 years) * Subject with a diagnosis of polycystic ovary syndrome confirmed by two of the Rotterdam Criteria * Subject with insulin resistance defined by: HOMA-IR of \> 2.00 Exclusion Criteria: * Pregnant and lactating women * Subjects known to have Cushing's syndrome, late onset of congenital adrenal hyperplasia, androgen-secreting tumors, uncontrolled thyroid disease, hyperprolactinemia * Known to have current medical condition, which, is judged by the Investigator could jeopardize subject's health or interfere with the study evaluation, such as diabetes mellitus, uncontrolled hypertension, other cardiovascular diseases, acute or chronic infections, and any known malignancies * Impaired renal function (serum creatinine level \> 1.5 ULN) * Impaired liver function (serum ALT level ≥ 2.5 ULN) * Medically-assisted weight loss with medications or surgical procedures * Currently having laparoscopic ovarian diathermy (LOD) * Currently under treatment with in vitro fertilization (IVF) techniques * Have been regularly taking any medications which affect insulin sensitivity as well as reproductive function (i.e. ovulation, menstrual cycle), within ≤ 3 months prior to screening * Participating in other clinical trial within 30 days prior to screening

Locations (2)

Department of Obstetrics and Gynecology, Faculty of Medicine, University of Padjadjaran, Hasan Sadikin Hospital

Bandung, West Java, Indonesia

Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Faculty of Medicine, University of Indonesia, dr. Cipto Mangunkusumo Hospital

Jakarta, Indonesia

Outcomes

Primary Outcomes

HOMA-IR reduction

HOMA-IR reduction from baseline to Month 6th (end of study)

Time frame: 6 months

Secondary Outcomes

Reduction of S/A ratio

Reduction (indicating improvement) of S/A ratio (i.e. ratio of mean stromal echogenicity to mean echogenicity of entire ovary) from baseline to Month 3rd and Month 6th (end of study)

Time frame: 3 and 6 months

Reduction of free testosterone level (calculated)

Reduction of free testosterone level (calculated) from baseline to Month 6th (end of study)

Time frame: 6 months

Change of luteinizing hormone (LH) level

Change of luteinizing hormone (LH) level from baseline to Month 6th (end of study)

Time frame: 6 months

Change of luteinizing hormone (LH) / follicle stimulating hormone (FSH) ratio

Change of luteinizing hormone (LH) / follicle stimulating hormone (FSH) ratio from baseline to Month 6th (end of study)

Time frame: 6 months

Change of Ferriman-Gallwey Score

Change of Ferriman-Gallwey Score from baseline to Month 3rd and Month 6th (end of study)

Time frame: 3 and 6 months

Improvement of glucose tolerance

Improvement of glucose tolerance (reduction of FPG and 2-hour PPPG) from baseline to Month 3rd and Month 6th (end of study)

Time frame: 3 and 6 months

Fasting insulin level reduction

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.